Lynozyfic (linvoseltamab-gcpt)

P2, N=34, Not yet recruiting, Medical College of Wisconsin | Initiation date: Mar 2026 --> Jul 2026

P1, N=26, Not yet recruiting, Regeneron Pharmaceuticals Inc.

In newly diagnosed MM (NDMM), minimal residual disease (MRD)-adaptive consolidation with linvoseltamab in IMMUNOPLANT converted persistent MRD positivity to MRD negativity in all evaluable patients, supporting biologically guided treatment intensification...In early relapsed/refractory MM (RRMM), the pioneering phase III MajesTEC-3 trial demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits with BsAb teclistamab plus daratumumab compared to other standard triplets, with response rates approaching those historically observed with chimeric antigen receptor (CAR) T cell therapy. A novel rational BsAb combination of BsAb elranatamab anda cereblon E3 ligase modulatory drug (CELMoD) iberdomide in MagnetisMM-30 showed promising synergy despite cytopenias and updates to combination BsAb targeting in RedirecTT-1 demonstrated major activity in difficult to treat extramedullary myeloma (EMM). First-in-human inMMyCAR data showcased the forefront of engineered immune strategies, by introducing an in vivo CAR-T product as a proof-of-concept platform, with tremendous potential to streamline the access to therapy. Collectively, these studies signal a shift toward earlier and adaptive immunotherapy in all phases of MM disease, while underscoring the importance of infection mitigation and long-term safety evaluation.

P3, N=915, Recruiting, Regeneron Pharmaceuticals

P1/2, N=150, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting

P3, N=1000, Recruiting, European Myeloma Network B.V.

P1/2, N=150, Not yet recruiting, Regeneron Pharmaceuticals

P1/2, N=30, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting

P2/3, N=1570, Not yet recruiting, Regeneron Pharmaceuticals

P2, N=40, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting

P2/3, N=713, Recruiting, European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale

P2/3, N=315, Not yet recruiting, Regeneron Pharmaceuticals Inc.